Pharma’s lobbying efforts: 10 drugmakers that spent the most so far in 2017

Pharmaceutical and medical device companies have collectively spent $208 million on lobbying efforts so far in 2017, according to data from the Center for Responsive Politics, a nonprofit, nonpartisan research group based in Washington D.C.

Advertisement

The data presented was last updated Oct. 21, 2017.

Here is the amount 10 pharmaceutical organizations spent on lobbying efforts so far this year.

1. Pharmaceutical Research & Manufacturers of America ($19.8 million)

2. Amgen ($8.6 million)

3. Pfizer ($8.5 million)

4. Bayer ($7.05 million)

5. Novartis ($7.04 million)

6. Eli Lilly ($5.55 million)

7. Merck ($5.44 million)

8. Teva Pharmaceuticals ($4.71 million)

9. AbbVie ($4.38 million)

10. Sanofi ($4.19 million)

More articles on supply chain:
Survey: 61% of patient advocacy groups have favorable view of devicemakers
Baxter expects $70M revenue loss from Hurricane Maria
Survey: 61% of patient advocacy groups have favorable view of devicemakers

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.